Core Viewpoint - uniQure N.V. has announced a public offering of 5,789,473 ordinary shares priced at $47.50 per share, aiming to raise approximately $300 million in gross proceeds before expenses [1] Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase 526,316 ordinary shares at the public offering price minus a nominal exercise price [1] - A 30-day option has been granted to underwriters to purchase up to 947,368 additional ordinary shares at the public offering price [1] - The offering is expected to close on or about September 29, 2025, pending customary closing conditions [1] Group 2: Management and Underwriters - Leerink Partners, Stifel, Guggenheim Securities, and Van Lanschot Kempen are acting as bookrunning managers for the offering, with H.C. Wainwright & Co. as the lead manager [2] Group 3: Company Background - uniQure is focused on gene therapy, with a significant milestone achieved through the approval of its gene therapy for hemophilia B, representing over a decade of research [5] - The company is advancing a pipeline of gene therapies targeting severe diseases, including Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [5]

Core Viewpoint - uniQure N.V. has initiated a $200 million underwritten public offering of its ordinary shares and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares sold [1][2]. Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [5]. - The company has achieved significant milestones in genomic medicine, particularly with its gene therapy for hemophilia B, which is based on over a decade of research and clinical development [5]. Offering Details - The public offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1]. - The offering is being conducted under an automatically effective shelf registration statement filed with the SEC [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]. Underwriters - The bookrunning managers for the offering include Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities [2].

Core Viewpoint - uniQure N.V. is set to report its second quarter 2025 financial results on July 29, 2025, and will host a conference call to discuss these results [1]. Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including a pipeline for treating Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases [3]. - The company achieved a significant milestone with the approval of its gene therapy for hemophilia B, marking a historic achievement in genomic medicine after over a decade of research and clinical development [3]. Event Details - The earnings call will be available via webcast on uniQure's website, with a replay archived for 90 days [2]. - Participants wishing to join by phone must register online to receive dial-in details and a personal PIN number [2].